Critical Review: Bioxytran (OTCMKTS:BIXT) versus enGene (NASDAQ:ENGN)

Bioxytran (OTCMKTS:BIXT) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bioxytran and enGene, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioxytran	0	0	0	0	0.00
enGene	2	8	4	0	2.14

enGene has a consensus target price of $11.05, indicating a potential upside of 527.58%. Given enGene’s stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Bioxytran.

Earnings & Valuation

This table compares Bioxytran and enGene”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioxytran	N/A	N/A	-$2.12 million	($0.02)	-1.44
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.81

Bioxytran is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.2% of enGene shares are held by institutional investors. 70.0% of Bioxytran shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Bioxytran and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioxytran	N/A	N/A	-737.48%
enGene	N/A	-56.06%	-45.64%

Volatility and Risk

Bioxytran has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500.

Summary

enGene beats Bioxytran on 6 of the 11 factors compared between the two stocks.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.